Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses...
Agios’ first-ever pediatric data readout missed the primary endpoint, with its drug Pyrukynd (mitapivat) not showing statistical significance in children with pyruvate kinase (PK) deficiency who are...
View ArticleGalapagos pauses blood cancer CAR-T therapy trial due to one Parkinsonism event
Galapagos has temporarily stopped enrolling patients into an early-phase test in patients with multiple myeloma after a neurological issue was raised. Elsewhere, the biotech expanded its deal with...
View ArticlePARP biotech backed by more than five pharmas closes after nine years
Ribon Therapeutics has shuttered after nine years, and one year after ending its preclinical research to focus on two early-stage PARP programs in cancer and atopic dermatitis. The Cambridge, MA-based...
View Article23andMe board rejects Anne Wojcicki’s take-private plan, requests changes
CEO Anne Wojcicki’s offer to take her genetic testing company 23andMe private for 40 cents a share has been met with resistance from her own board. In a letter sent Friday, a special committee of board...
View ArticleKyowa Kirin divests China unit, prunes discovery and manufacturing work
Kyowa Kirin is selling off its China business and transitioning to a research organization in a shake-up that could lead to major cuts to the company’s in-house discovery and CMC work. The Japanese...
View ArticleApogee and Spyre founder launches another autoimmune biotech, and it's got...
Amid an action-packed Thursday, another biotech launched to take on the ever-popular landscape of autoimmune drug development. And the new Boston-area biotech comes from a repeat creator: Paragon...
View ArticleIn Japan, sales of Eisai and Biogen's Alzheimer's drug begin to accelerate
Biogen and Eisai’s Alzheimer’s drug Leqembi is off to a slow start in the US. But it’s big in Japan. On Friday, Eisai revealed in an investor presentation that Japanese revenue accounted for 1.5...
View ArticleExclusive: Devoted Health raises $112M, plots insurance markets expansion
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Devoted Health just nabbed another $112 million in venture funding to fuel its push into seven new...
View ArticleClik here to view.
Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical...
PHILADELPHIA — Among the many mysteries of Alzheimer’s disease is the role that iron plays. The metal is vital for transporting oxygen in the blood and producing energy from mitochondria, but some...
View ArticleMassachusetts' plan for $1B in life science investment stalls in state...
Massachusetts Gov. Maura Healey’s proposal to invest another $1 billion in life sciences over the next 10 years has been imperiled after failing to make it through the state’s legislative body before...
View ArticleDoses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA...
Doses of Eli Lilly’s blockbuster weight loss and diabetes drugs that were listed as in short supply no longer are, according to the FDA’s database that tracks drugs in limited supply. The agency’s...
View ArticleAdvisory committee votes in favor of Zevra Therapeutics' rare genetic disease...
A panel of outside advisors to the FDA voted 11-5 in favor of Zevra Therapeutics’ drug for a rare genetic condition called Niemann-Pick disease type C, saying that it is effective based on current...
View ArticleEisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleBristol Myers Squibb returns TIGIT bispecific to Agenus, ends $1.5B+ pact
Bristol Myers Squibb has backed out of a TIGIT partnership with Agenus, returning a bispecific that it had paid $200 million upfront to license. The pharma giant is ending the deal “as part of a...
View ArticleClik here to view.
BioNTech says no to Phase 3 with Genmab’s bispecific antibody
BioNTech has opted not to further contribute to a co-owned PD-L1 x 4-1BB bispecific antibody with Genmab, meaning the Danish biotech will have to move into Phase 3 later this year on its own. The...
View ArticleClik here to view.
Bayer plans label expansion for Kerendia after Phase 3 win in heart failure
Bayer touted a win in a Phase 3 heart failure study with Kerendia on Monday, announcing that the drug hit the primary endpoint in the study. Though the German drugmaker didn’t release any data with the...
View ArticleFlorida CNS gene therapy biotech shuts down
Seven-year-old gene therapy startup Lacerta Therapeutics has folded and sold its assets, a board member confirmed to Endpoints News. The University of Florida spinout, based in Alachua, Florida, had...
View ArticleFDA wants new trial of Actinium Pharmaceuticals' radioactive iodine drug,...
Actinium Pharmaceuticals is no longer planning to move forward with its iodine-based drug independently after the FDA said a new clinical trial would be needed to apply for approval. Actinium was...
View ArticleMBX Biosciences rakes in $63.5M for peptide therapies
MBX Biosciences raised $63.5 million in a Series C funding round, two years after closing a $115 million Series B. The biotech, which is focusing on peptide therapies for endocrine and metabolic...
View ArticleLayoffs at Sumitomo; Galderma and L’Oréal strike a deal
Plus, news about Eiger BioPharmaceuticals: Sumitomo cuts workers: The Japanese pharma is laying off 53 people in Marlborough, MA, according to an August 1 WARN notice. The layoffs will happen at the...
View Article